6533b823fe1ef96bd127e08a
RESEARCH PRODUCT
A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer
R. SalazarJ. GullboK. JohanssonJ. VermorkenAndrés CervantesP. MorsingN. Lindland RoestT. Anderssonsubject
Oncologymedicine.medical_specialtybusiness.industryColorectal cancermedicine.medical_treatmentHematologymedicine.diseaseWNT5AOncologyInternal medicineMedicineIn patientOpen labelbusinessNeoadjuvant therapyWnt 5a proteinyear | journal | country | edition | language |
---|---|---|---|---|
2019-07-01 | Annals of Oncology |